Azithramycine

Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.

Cross Reference

Introduction

To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Azithramycine?

Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Azithramycine

MeSH term MeSH ID Detail
Periodontitis D010518 22 associated lipids
Gastrointestinal Diseases D005767 20 associated lipids
Vomiting D014839 21 associated lipids
Fever D005334 35 associated lipids
Anaphylaxis D000707 35 associated lipids
Pregnancy Complications, Infectious D011251 11 associated lipids
Toxoplasmosis D014123 9 associated lipids
Toxoplasmosis, Congenital D014125 2 associated lipids
Otitis Media with Effusion D010034 9 associated lipids
Shock, Septic D012772 11 associated lipids
Per page 10 20 50 100 | Total 276

PubChem Associated disorders and diseases

What pathways are associated with Azithramycine

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Azithramycine?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Azithramycine?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Azithramycine?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Azithramycine?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Azithramycine?

Mouse Model

Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).

Knock-out

Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).

Tissue Model

Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Azithramycine

Download all related citations
Per page 10 20 50 100 | Total 4404
Authors Title Published Journal PubMed Link
Vranes J et al. Influence of subinhibitory concentrations of ceftazidime, ciprofloxacin and azithromycin on the morphology and adherence of P-fimbriated escherichia coli. 1996 J Chemother pmid:8873829
Laing RB et al. Clinical features, outcome and survival from cerebral toxoplasmosis in Edinburgh AIDS patients. 1996 Int J STD AIDS pmid:8876356
Tansey MJ and Moe JB Severe neutropenia and prophylactic doses of rifabutin. 1996 Lancet pmid:8950911
Sefton AM et al. Azithromycin in the treatment of periodontal disease. Effect on microbial flora. 1996 J. Clin. Periodontol. pmid:8951627
Griffith DE et al. Varying dosages of rifabutin affect white blood cell and platelet counts in human immunodeficiency virus--negative patients who are receiving multidrug regimens for pulmonary Mycobacterium avium complex disease. 1996 Clin. Infect. Dis. pmid:8953085
Schouten JT and Whittemore S Recent development in the treatment and prevention of disseminated Mycobacterium avium complex (MAC). 1996 STEP Perspect pmid:11364267
Bertoni G et al. Triple therapy with azithromycin, omeprazole, and amoxicillin is highly effective in the eradication of Helicobacter pylori: a controlled trial versus omeprazole plus amoxicillin. 1996 Am. J. Gastroenterol. pmid:8607489
Hulten K et al. In-vitro activity of azithromycin in against intracellular Helicobacter pylori. 1996 J. Antimicrob. Chemother. pmid:9182105
Di Mario F et al. Azithromycin for the cure of Helicobacter pylori infection. 1996 Am. J. Gastroenterol. pmid:8607490
Na-Bangchang K et al. Activity of artemether-azithromycin versus artemether-doxycycline in the treatment of multiple drug resistant falciparum malaria. 1996 Southeast Asian J. Trop. Med. Public Health pmid:9185262
Wittner M et al. Atovaquone in the treatment of Babesia microti infections in hamsters. 1996 Am. J. Trop. Med. Hyg. pmid:8780464
Apseloff G et al. Severe neutropenia caused by recommended prophylactic doses of rifabutin. 1996 Lancet pmid:8782773
ZaÄ­tseva EA et al. [Comparative study of the antimicrobial activity of pefloxacin, ciprofloxacin, norfloxacin and azithromycin with respect to Strains of Yersinia pseudotuberculosis]. 1996 Antibiot. Khimioter. pmid:8762820
Lode H et al. Azithromycin--review of key chemical, pharmacokinetic and microbiological features. 1996 J. Antimicrob. Chemother. pmid:8818841
Girard AE et al. Correlation of increased azithromycin concentrations with phagocyte infiltration into sites of localized infection. 1996 J. Antimicrob. Chemother. pmid:8818842
Girard D et al. Influence of immunosuppression on the pharmacokinetics and pharmacodynamics of azithromycin in infected mouse tissues. 1996 J. Antimicrob. Chemother. pmid:8818843
Foulds G et al. The absence of an effect of food on the bioavailability of azithromycin administered as tablets, sachet or suspension. 1996 J. Antimicrob. Chemother. pmid:8818844
Vaudaux BP et al. Concentrations of azithromycin in tonsilar and/or adenoid tissue from paediatric patients. 1996 J. Antimicrob. Chemother. pmid:8818845
Pukander J and Rautianen M Penetration of azithromycin into middle ear effusions in acute and secretory otitis media in children. 1996 J. Antimicrob. Chemother. pmid:8818846
Rodriguez AF An open study to compare azithromycin with cefaclor in the treatment of children with acute otitis media. 1996 J. Antimicrob. Chemother. pmid:8818847
O'Doherty B An open comparative study of azithromycin versus cefaclor in the treatment of patients with upper respiratory tract infections. 1996 J. Antimicrob. Chemother. pmid:8818848
Dupont C et al. Microbiological findings about pulmonary cryptosporidiosis in two AIDS patients. 1996 J. Clin. Microbiol. pmid:8748314
Wildfeuer A et al. Uptake of azithromycin by various cells and its intracellular activity under in vivo conditions. 1996 Antimicrob. Agents Chemother. pmid:8787883
Meloni G and Meloni T Azithromycin vs. doxycycline for Mediterranean spotted fever. 1996 Pediatr. Infect. Dis. J. pmid:8933556
Jackson MA et al. Breakthrough sepsis in macrolide-resistant pneumococcal infection. 1996 Pediatr. Infect. Dis. J. pmid:8933560
Hicks P et al. Azithromycin therapy for Cryptosporidium parvum infection in four children infected with human immunodeficiency virus. 1996 J. Pediatr. pmid:8765631
Boran M et al. Improvement in cyclosporine A associated gingival hyperplasia with azithromycin therapy. 1996 Transplant. Proc. pmid:8769234
Luft BJ et al. Azithromycin compared with amoxicillin in the treatment of erythema migrans. A double-blind, randomized, controlled trial. 1996 Ann. Intern. Med. pmid:8610947
Ridgway GL Azithromycin in sexually transmitted diseases. 1996 Int J STD AIDS pmid:8652719
Akita H et al. [Bacteriological, pharmacokinetic and clinical evaluation of azithromycin in the pediatric field]. 1996 Jpn J Antibiot pmid:8986553
Nishimura T et al. [Clinical evaluation of azithromycin in pediatric infections]. 1996 Jpn J Antibiot pmid:8986554
Young LS Azithromycin in the management of opportunistic infections. 1996 Int J STD AIDS pmid:8652721
Chang HR The potential role of azithromycin in the treatment of prophylaxis of toxoplasmosis. 1996 Int J STD AIDS pmid:8652722
Waugh MA Azithromycin in gonorrhoea. 1996 Int J STD AIDS pmid:8652723
Young LS Treatment and prophylaxis of Mycobacterium avium complex. 1996 Int J STD AIDS pmid:8652724
Hoepelman IM Human cryptosporidiosis. 1996 Int J STD AIDS pmid:8652725
McCutchan JA Azithromycin in the prophylaxis of opportunistic infections in AIDS. 1996 Int J STD AIDS pmid:8652726
Ridgway GL Azithromycin in the management of Chlamydia trachomatis infections. 1996 Int J STD AIDS pmid:8652727
Ballard RC et al. Treatment of chancroid with azithromycin. 1996 Int J STD AIDS pmid:8652728
Bowden FJ et al. Pilot study of azithromycin in the treatment of genital donovanosis. 1996 Genitourin Med pmid:8655160
Luke DR et al. Safety, toleration, and pharmacokinetics of intravenous azithromycin. 1996 Antimicrob. Agents Chemother. pmid:8913468
Olsen KM et al. Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses. 1996 Antimicrob. Agents Chemother. pmid:8913469
Kuo CC et al. In vitro activities of azithromycin, clarithromycin, and other antibiotics against Chlamydia pneumoniae. 1996 Antimicrob. Agents Chemother. pmid:8913488
Aoyama T et al. Efficacy of short-term treatment of pertussis with clarithromycin and azithromycin. 1996 J. Pediatr. pmid:8917247
Pacifico L et al. Comparative efficacy and safety of 3-day azithromycin and 10-day penicillin V treatment of group A beta-hemolytic streptococcal pharyngitis in children. 1996 Antimicrob. Agents Chemother. pmid:8849215
Jaruratanasirikul S et al. Distribution of azithromycin into brain tissue, cerebrospinal fluid, and aqueous humor of the eye. 1996 Antimicrob. Agents Chemother. pmid:8851625
Bedos JP and Veber B [Lower respiratory infections: predictive factors of therapeutic response]. 1996 Rev Pneumol Clin pmid:9033917
Zuck P [Efficacy of a 5-day treatment with an azalide (azithromycin) in superinfections of chronic bronchitis]. 1996 Rev Pneumol Clin pmid:9033919
Hayle R et al. Efficacy and safety of azithromycin versus phenoxymethylpenicillin in the treatment of acute maxillary sinusitis. 1996 Eur. J. Clin. Microbiol. Infect. Dis. pmid:8997555
Magid D et al. Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: an incremental cost-effectiveness analysis. 1996 Ann. Intern. Med. pmid:8554247
Genç M and Mårdh A A cost-effectiveness analysis of screening and treatment for Chlamydia trachomatis infection in asymptomatic women. 1996 Ann. Intern. Med. pmid:7503471
Three new studies expand understanding of MAC therapy. 1996 Am J Health Syst Pharm pmid:8899122
Evans LA et al. Predicting injection site muscle damage. III: Evaluation of intramuscular formulations in the L6 cell model. 1996 Pharm. Res. pmid:8899856
O'Doherty B Azithromycin versus penicillin V in the treatment of paediatric patients with acute streptococcal pharyngitis/tonsillitis. Paediatric Azithromycin Study Group. 1996 Eur. J. Clin. Microbiol. Infect. Dis. pmid:8922571
Dunn CJ and Barradell LB Azithromycin. A review of its pharmacological properties and use as 3-day therapy in respiratory tract infections. 1996 Drugs pmid:8882383
Gnarpe J et al. In vitro activities of azithromycin and doxycycline against 15 isolates of Chlamydia pneumoniae. 1996 Antimicrob. Agents Chemother. pmid:8843291
Keysary A et al. The in-vitro anti-rickettsial activity of macrolides. 1996 J. Antimicrob. Chemother. pmid:8937968
Mein J et al. Donovanosis: sequelae of severe disease and successful azithromycin treatment. 1996 Int J STD AIDS pmid:8940677
Hoque S et al. Rhodococcus equi in CAPD-associated peritonitis treated with azithromycin. 1996 Nephrol. Dial. Transplant. pmid:8941608
Wiselka MJ et al. Response to oral and intravenous azithromycin in a patient with toxoplasma encephalitis and AIDS. 1996 J. Infect. pmid:8945715
Gómez E et al. Interaction between azithromycin and cyclosporin? 1996 Nephron pmid:8856287
Delmée M et al. In vitro susceptibilities of 180 clinical isolates of Haemophilus influenzae to ampicillin, amoxycillin/clavulanate, cefaclor, cefuroxime, cefotaxime, clarithromycin, and azithromycin. 1996 Acta Clin Belg pmid:8858889
Watt B et al. Comparative activity of azithromycin against clinical isolates of mycobacteria. 1996 J. Antimicrob. Chemother. pmid:8889727
Mashkilleyson AL et al. Treatment of syphilis with azithromycin. 1996 Int J STD AIDS pmid:8652720
Patel KB et al. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. 1996 Antimicrob. Agents Chemother. pmid:8891147
Amsden GW Erythromycin, clarithromycin, and azithromycin: are the differences real? 1996 Jan-Feb Clin Ther pmid:8851453
Preac Mursic V et al. Kill kinetics of Borrelia burgdorferi and bacterial findings in relation to the treatment of Lyme borreliosis. 1996 Jan-Feb Infection pmid:8852456
Baradaran-Dilmaghani R and Stanek G In vitro susceptibility of thirty Borrelia strains from various sources against eight antimicrobial chemotherapeutics. 1996 Jan-Feb Infection pmid:8852472
Strle F et al. Azithromycin and doxycycline for treatment of Borrelia culture-positive erythema migrans. 1996 Jan-Feb Infection pmid:8852473
Fontán PA et al. Haemophilus influenzae type b exoproducts induce chemotaxis and macrolide antibiotic release by human polymorphonuclear leukocytes. 1996 Jan-Feb Chemotherapy pmid:8751269
Ehret JM et al. A clinical isolate of Neisseria gonorrhoeae with in vitro resistance to erythromycin and decreased susceptibility to azithromycin. 1996 Jul-Aug Sex Transm Dis pmid:8836018
Lane G Increased hypoprothrombinemic effect of warfarin possibly induced by azithromycin. 1996 Jul-Aug Ann Pharmacother pmid:8826581
Diculencu D et al. [The postantibiotic effect of azithromycin on respiratory pathogens]. 1996 Jul-Dec Rev Med Chir Soc Med Nat Iasi pmid:9455450
Carlin EM and Barton SE Azithromycin as the first-line treatment of non-gonococcal urethritis (NGU): a study of follow-up rates, contact attendance and patients' treatment preference. 1996 May-Jun Int J STD AIDS pmid:8799780
Shanks GD et al. Azithromycin prophylaxis prevents epidemic dysentery. 1996 May-Jun Trans. R. Soc. Trop. Med. Hyg. pmid:8758091
Adam D et al. Re: A. Bauernfeind et al.: Comparative pharmacodynamics of clarithromycin and azithromycin against respiratory pathogens (Infection 23 [1995] 316-321) 1996 May-Jun Infection pmid:8811372
Vranes J Effect of subinhibitory concentrations of ceftazidime, ciprofloxacin, and azithromycin on the hemagglutination and adherence of uropathogenic Escherichia coli strains. 1996 May-Jun Chemotherapy pmid:8983884
Ichimiya T et al. The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro. 1996 May-Jun Chemotherapy pmid:8983885
Galova K et al. Multicenter randomized study of two once daily regimens in the initial management of community-acquired respiratory tract infections in 163 children: azithromycin versus ceftibuten. 1996 May-Jun Chemotherapy pmid:8983893
Burke SM Azithromycin: only once a day. 1996 May-Jun MCN Am J Matern Child Nurs pmid:8857402
Ripa S et al. A linear model for the pharmacokinetics of azithromycin in healthy volunteers. 1996 Nov-Dec Chemotherapy pmid:8957574
D'Amico R ICAAC update on opportunistic infections. 1996 Nov-Dec Posit Aware pmid:11363974
Wendel TD 1-day azithromycin was as effective as 7-day doxycycline for nongonococcal urethritis syndrome in men. 1996 Nov-Dec ACP J. Club pmid:8912627
Peeling RW and Brunham RC Chlamydiae as pathogens: new species and new issues. 1996 Oct-Dec Emerging Infect. Dis. pmid:8969247
Biebuyck XA Comparison of azithromycin and co-amoxiclav in the treatment of acute tracheobronchitis and acute infectious exacerbations of chronic bronchitis in adults. Azithromycin Study Group. 1996 Sep-Oct J. Int. Med. Res. pmid:8895044
Pacifico L and Chiesa C Efficacy of three-day azithromycin vs. ten-day penicillin V in the treatment of streptococcal pharyngitis. 1997 Pediatr. Infect. Dis. J. pmid:9154566
Fernandez-Obregon AC Azithromycin for the treatment of acne. 1997 Int. J. Dermatol. pmid:9159021
Nightingale CH Pharmacokinetics and pharmacodynamics of newer macrolides. 1997 Pediatr. Infect. Dis. J. pmid:9109156
Block SL Causative pathogens, antibiotic resistance and therapeutic considerations in acute otitis media. 1997 Pediatr. Infect. Dis. J. pmid:9109158
Tarlow MJ et al. Future indications for macrolides. 1997 Pediatr. Infect. Dis. J. pmid:9109159
Blanshard C et al. Pilot studies of azithromycin, letrazuril and paromomycin in the treatment of cryptosporidiosis. 1997 Int J STD AIDS pmid:9061412
Young H et al. Azithromycin and erythromycin resistant Neisseria gonorrhoeae following treatment with azithromycin. 1997 Int J STD AIDS pmid:9175650
Hoppe JE and Tschirner T Comparison of Etest and agar dilution for testing the activity of three macrolides against Bordetella parapertussis. 1997 Diagn. Microbiol. Infect. Dis. pmid:9218920
Visalli MA et al. Susceptibility of twenty penicillin-susceptible and -resistant pneumococci to levofloxacin, ciprofloxacin, ofloxacin, erythromycin, azithromycin, and clarithromycin by MIC and time-kill. 1997 Diagn. Microbiol. Infect. Dis. pmid:9294703
Dautzenberg B Rationale for the prevention of disseminated Mycobacterium avium-intracellulare complex disease. 1997 Drugs pmid:9358194
Handsfield HH Azithromycin in gonorrhoea. 1997 Int J STD AIDS pmid:9228599
Cohn DL Prevention strategies for Mycobacterium avium-intracellulare complex (MAC) infection. A review of recent studies in patients with AIDS. 1997 Drugs pmid:9358195
Marone P et al. Rapid drug susceptibility of Mycobacterium avium complex using a fluorescence quenching method. 1997 J Chemother pmid:9269603
Gruber F et al. Comparative trial of azithromycin and ciprofloxacin in the treatment of gonorrhea. 1997 J Chemother pmid:9269606
Jepras RI et al. Rapid assessment of antibiotic effects on Escherichia coli by bis-(1,3-dibutylbarbituric acid) trimethine oxonol and flow cytometry. 1997 Antimicrob. Agents Chemother. pmid:9303401